|
EML1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.22044604925031E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.44089209850063E-16 |
| Normal-vs-Stage2 |
2.256400E-03 |
| Normal-vs-Stage3 |
1.62592161956354E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
1.801670E-04 |
| Stage1-vs-Stage3 |
2.334000E-01 |
| Stage1-vs-Stage4 |
2.304799999997E-05 |
| Stage2-vs-Stage3 |
1.421830E-04 |
| Stage2-vs-Stage4 |
1.01319999945559E-07 |
| Stage3-vs-Stage4 |
2.725600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.53850002024581E-09 |
| Normal-vs-Asian |
<1E-12 |
| Caucasian-vs-AfricanAmerican |
9.947000E-01 |
| Caucasian-vs-Asian |
2.374400E-01 |
| AfricanAmerican-vs-Asian |
5.463400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.86433157379452E-13 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
5.715200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62581059726108E-12 |
| Normal-vs-Age(61-80Yrs) |
3.43179928918858E-11 |
| Normal-vs-Age(81-100Yrs) |
2.01729999999012E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.708000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.180580E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.972200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.539600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.190400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.286400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.94373422807348E-12 |
| Classical-VS-Follicular |
7.49570000513344E-08 |
| Classical-VS-Other |
9.335000E-01 |
| Classical-VS-Normal |
1.6242562850266E-12 |
| Tall-VS-Follicular |
1.62447832963153E-12 |
| Tall-VS-Other |
7.118200E-02 |
| Tall-VS-Normal |
1.62436730732907E-12 |
| Follicular-VS-Other |
7.255900E-02 |
| Follicular-VS-Normal |
9.218700E-04 |
| Other-VS-Normal |
6.20519999999791E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.80617800902428E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
4.79620000382042E-08 |
|
|
